Trends in Antipsychotic and Mood Stabilizer Prescribing in Long-Term Care in the U.S.: 2011-2014.

Journal of the American Medical Directors Association
Lauren B GerlachDonovan T Maust

Abstract

The Centers for Medicare and Medicaid Services' National Partnership to Improve Dementia Care in Nursing Homes focuses on but is not limited to long-term care (LTC) residents with dementia; the potential impact on residents with other diagnoses is unclear. We sought to determine whether resident subpopulations experienced changes in antipsychotic and mood stabilizer prescribing. Repeated cross-sectional analysis of a 20% Medicare sample, 2011-2014. Fee-for-service Medicare beneficiaries with Part D coverage in LTC (n = 562,485) and a secondary analysis limited to persons with depression or bipolar disorder (n = 139,071). Main outcome was quarterly predicted probability of treatment with an antipsychotic or mood stabilizer. From 2011 to 2014, the adjusted predicted probability (APP) of antipsychotic treatment fell from 0.120 [95% confidence interval (CI) 0.119-0.121] to 0.100 (95% CI 0.099-0.101; P < .001). Use decreased for all age, sex, and racial/ethnic groups; the decline was larger for persons with dementia (P < .001). The APP of mood stabilizer use grew from 0.140 (95% CI 0.139-0.141) to 0.185 (95% CI 0.184-0.186), growth slightly larger among persons without dementia (P < .001). Among persons with depression or bipolar di...Continue Reading

References

Sep 1, 1992·Journal of the American Geriatrics Society·R Elon, L G Pawlson
Jan 1, 1995·The Journal of Neuropsychiatry and Clinical Neurosciences·A D LottM A Keys
Oct 1, 1995·Journal of Geriatric Psychiatry and Neurology·P N TariotI R Katz
Feb 7, 1998·Medical Care·A ElixhauserR M Coffey
Feb 1, 2000·Journal of Clinical Psychopharmacology·N HerrmannM Myszak
Mar 29, 2002·International Journal of Geriatric Psychiatry·Jennifer L PayneConstantine G Lyketsos
May 5, 2009·General Hospital Psychiatry·John W WilliamsLynn Whitener
May 6, 2009·Health Affairs·David C GrabowskiVincent Mor
Sep 29, 2011·JAMA : the Journal of the American Medical Association·Alicia Ruelaz MaherPaul G Shekelle
Dec 24, 2011·The American Journal of Psychiatry·Helen C KalesFrederic C Blow
Feb 7, 2013·JAMA : the Journal of the American Medical Association·Becky A BriesacherJerry H Gurwitz
Mar 4, 2015·BMJ : British Medical Journal·Helen C KalesConstantine G Lyketsos
Nov 4, 2015·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Akshya VasudevMuhammad Mamdani
Jan 13, 2017·Aging & Mental Health·Brianne L Olivieri-MuiBecky Briesacher
Aug 3, 2017·The New England Journal of Medicine·Christopher W Goodman, Allan S Brett
Jan 4, 2018·JAMA Internal Medicine·Michael E Johansen
Mar 1, 2018·The Australian and New Zealand Journal of Psychiatry·Juanita WestburyGregory Peterson
Mar 26, 2019·JAMA Internal Medicine·Christopher W Goodman, Allan S Brett

❮ Previous
Next ❯

Citations

Dec 22, 2020·Current Treatment Options in Psychiatry·Lauren B Gerlach, Helen C Kales

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Related Papers

Chūdoku kenkyū : Chūdoku Kenkyūkai jun kikanshi = The Japanese journal of toxicology
Masami Tensho
© 2021 Meta ULC. All rights reserved